Compare Neurocrine Biosciences Inc (NBIX) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nike Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Nike Inc trades at $37.41 (market cap $56.52B). The key difference: Nike Inc is far larger — about 3.6× Neurocrine Biosciences Inc's market cap, and Nike Inc pays a 4.3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NKE | |
|---|---|---|
Market Cap | $15.77B | $56.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $74.57 |
52-Week Low | $123.10 | $37.35 |
Enterprise Value | $15.78B | $58.53B |
Volume | — | 8,887,180 |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Nike (NKE) trades at $37.35, down 2.73% amid bearish technical signals and recent earnings volatility. The stock shows strong profitability metrics with 42.91% gross margins and 22.14% ROE, but faces revenue pressure with FY2025 sales declining to $46.31B. Analyst consensus remains positive with a $49.81 price target, though technical indicators signal caution with 17 sell signals versus 3 buy signals.
Nike's investment case balances strong brand equity and recent earnings beats against China market challenges and inventory pressures. The stock offers 33% upside to consensus targets but requires successful execution of the 'Win Now' turnaround strategy to overcome near-term headwinds in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
